Severe Immune-related Adverse Events and Their Effect on Survival in Patients With Advanced Non–small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors
Treatment with anti-PD-1 was associated with an increased risk of severe irAEs. The incidence of severe irAEs was not associated with an improved survival rate.
Authors
- Utae Katsushima
- Takashi Nojiri (ORCID: https://orcid.org/0000-0002-7049-9877)
- Kiyotsugu Iede (ORCID: https://orcid.org/0000-0001-9366-759X)
- Yuki Takeyasu (ORCID: https://orcid.org/0000-0003-3295-0273)
- Masahiko Higashiyama
- Akiisa Omura (ORCID: https://orcid.org/0000-0002-2810-0922)
- Hiroshi Nishimura
Institutions
- Kansai Medical University (JP)
- Himeji University (JP)
- Higashiosaka College & Higashiosaka Junior College (JP)
- Higashi Osaka City General Hospital (JP)
- Himeji Medical Center (JP)
Publication Details
- Journal
- Cancer Diagnosis & Prognosis
- Published
- 2026-01-03
- DOI
- https://doi.org/10.21873/cdp.10511
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00